Reply to: “Comments on the paper ‘Extensive epigenomic dysregulation is a hallmark of homologous recombination deficiency in triple‐negative breast cancer’ by Y. Chen et al.”

Ähnliche Einträge

• Comments on the paper “Extensive epigenomic dysregulation is a hallmark of homologous recombination deficiency in triple‐negative breast cancer” by Y. Chen et al.
  von: Per Eystein Lønning, et al.
  Veröffentlicht: (2025)
• Multi‐omic analysis of dysregulated pathways in triple negative breast cancer
  von: Fatima Sajjad, et al.
  Veröffentlicht: (2024)
• Poly (adenosine diphosphate‐ribose) polymerase inhibitors in the treatment of triple‐negative breast cancer with homologous repair deficiency
  von: Peng Yuan, et al.
  Veröffentlicht: (2024)
• Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data
  von: Rong Zhu, et al.
  Veröffentlicht: (2025)
• A new peptide inhibitor of C1QBP exhibits potent anti‐tumour activity against triple negative breast cancer by impairing mitochondrial function and suppressing homologous recombination repair
  von: Xingxing Li, et al.
  Veröffentlicht: (2025)